Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2018-99-111823

Published: 2018

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Priya Sriskandarajah, MBBS, BSc, MRCP, Kevin Boyd, Wen Xu, MD, Irene Moreno Candilejo, MD, Sidra Ellis, Amy Price, Amy L Sherborne, PhD, James Croft, MBBS, BSc, Vallari Shah, MBBS, Joanna Dawes, PhD, Mona Parmar, Alison Turner, Emma Hall, BSc, MSc, PhD, Nina Tunariu, MBBS, MDes, MRCP, FRCR, Juanita S Lopez, MB BChir, MRCP, PhD, Johann S. de Bono, Udai Banerji, MBBS, MD DNB, PhD FRCP, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2018-99-111821

Published: 2018

Journal Articles

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Debbie Sherratt, Sadie Reed, PhD, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2018-99-111835

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Blood (2016) 128 (4): 497–503.

https://doi.org/10.1182/blood-2016-02-700872

Published: 2016

Journal Articles

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Noopur Raje, Ian Chau, David M. Hyman, Vincent Ribrag, Jean-Yves Blay, Josep Tabernero, Maria Elena Elez-Fernandez, Jürgen S. Wolf, Florin Sirzen, Andrew Yee, Jason Faris, Martin Kaiser, Heather Landau, Jean-Marie Michot, Luisa Veronese, Martina Makrutzki, Susan Francis Lasserre, Igor Puzanov, Jose Baselga

Blood (2015) 126 (23): 4263.

https://doi.org/10.1182/blood.V126.23.4263.4263

Published: 2015

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

Improved Risk Stratification in Myeloma Using Microrna-Based Classifier

Ping Wu, MBBS, MSc, Luca Agnelli, PhD, Brian A Walker, BSc, PhD, Katia Todoerti, David C Johnson, PhD, Martin Kaiser, MD, Christopher P Wardell, PhD, Walter M Gregory, PhD, Faith E. Davies, MD, Daniel Brewer, PhD, Antonino Neri, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 932.

https://doi.org/10.1182/blood.V120.21.932.932

Published: 2012

Journal Articles

Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia

Andrea Kühnl, Nicola Gökbuget, Martin Kaiser, Cornelia Schlee, Andrea Stroux, Thomas Burmeister, Liliana H. Mochmann, Dieter Hoelzer, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D. Baldus

Blood (2011) 118 (24): 6362–6367.

https://doi.org/10.1182/blood-2011-04-350850

Published: 2011

Journal Articles

The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells Via Upregulation of Vitamin D Receptor Signaling

Martin Kaiser, Maren Mieth, Orhan Sezer, MD, PhD, Ulrike Heider

Blood (2010) 116 (21): 1899.

https://doi.org/10.1182/blood.V116.21.1899.1899

Published: 2010

Journal Articles

Antileukemic Activity of the HSP70 Inhibitor Pifithrin-μ

Martin Kaiser, Andrea Kuehnl, Jutta Ortiz-Tanchez, Ouidad Benlasfer, Cornelia Schlee, Sandra Heesch, Eckhard Thiel, Claudia Baldus

Blood (2010) 116 (21): 3306.

https://doi.org/10.1182/blood.V116.21.3306.3306

Published: 2010

Journal Articles

Decrease in CD4+ T Cells in Multiple Myeloma Patients Receiving Bortezomib.

Ulrike Heider, MD, Jessica Rademacher, MD, Martin Kaiser, MD, Ivana von Metzler, MD, Karin Marquardt, Orhan Sezer, MD, PhD

Blood (2009) 114 (22): 3865.

https://doi.org/10.1182/blood.V114.22.3865.3865

Published: 2009

Journal Articles

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Christian Jakob, MD,, Theresa Wernecke, MD, Jan Sterz, MD, Andrea Goerke, MD, Ulrike Heider, MD, Martin Kaiser, MD, Maren Mieth, PhD, Susanne Ziefle, MD, Orhan Sezer, MD, PhD

Blood (2009) 114 (22): 2802.

https://doi.org/10.1182/blood.V114.22.2802.2802

Published: 2009

NARROW

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Improved Risk Stratification in Myeloma Using Microrna-Based Classifier

Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia

The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells Via Upregulation of Vitamin D Receptor Signaling

Antileukemic Activity of the HSP70 Inhibitor Pifithrin-μ

Decrease in CD4+ T Cells in Multiple Myeloma Patients Receiving Bortezomib.

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only